AAAAAA

   
Results: 1-16 |
Results: 16
Pre-targeted locoregional radioimmunotherapy with 9(0Y)-biotin in glioma patients: Phase I study and preliminary therapeutic results
Authors: Paganelli, G Bartolomei, M Ferrari, M Cremonesi, M Broggi, G Maira, G Sturiale, C Grana, C Prisco, G Gatti, M Caliceti, P Chinol, M
Citation: G. Paganelli et al., Pre-targeted locoregional radioimmunotherapy with 9(0Y)-biotin in glioma patients: Phase I study and preliminary therapeutic results, CANC BIO R, 16(3), 2001, pp. 227-235
Receptor-mediated radiotherapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide
Authors: Paganelli, G Zoboli, S Cremonesi, M Bodei, L Ferrari, M Grana, C Bartolomei, M Orsi, F De Cicco, C Maacke, HR Chinol, M de Braud, F
Citation: G. Paganelli et al., Receptor-mediated radiotherapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide, EUR J NUCL, 28(4), 2001, pp. 426-434
The humoral immune response to macrocyclic chelating agent DOTA depends onthe carrier molecule
Authors: Perico, ME Chinol, M Nacca, A Luison, E Paganelli, G Canevari, S
Citation: Me. Perico et al., The humoral immune response to macrocyclic chelating agent DOTA depends onthe carrier molecule, J NUCL MED, 42(11), 2001, pp. 1697-1703
In-111-labeled 1,4,7,10-tetraazacyclododecane-N,N',N''N'''-tetraacetic acid-Lys(8)-vasotocin: A new powerful radioligand for oxytocin receptor-expressing tumors
Authors: Bussolati, G Chinol, M Chini, B Nacca, A Cassoni, P Paganelli, G
Citation: G. Bussolati et al., In-111-labeled 1,4,7,10-tetraazacyclododecane-N,N',N''N'''-tetraacetic acid-Lys(8)-vasotocin: A new powerful radioligand for oxytocin receptor-expressing tumors, CANCER RES, 61(11), 2001, pp. 4393-4397
Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience
Authors: Cremonesi, M Ferrari, M Chinol, M Bartolomei, M Stabin, MG Sacco, E Fiorenza, M Tosi, G Paganelli, G
Citation: M. Cremonesi et al., Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience, Q J NUCL M, 44(4), 2000, pp. 325-332
Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging
Authors: Guttinger, M Guidi, F Chinol, M Reali, E Veglia, F Viale, G Paganelli, G Corti, A Siccardi, AG
Citation: M. Guttinger et al., Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging, CANCER RES, 60(15), 2000, pp. 4211-4215
Pretargeted radioimmunotherapy of cancer
Authors: Chinol, M Grana, C Gennari, R Cremonesi, M Geraghty, JG Paganelli, G
Citation: M. Chinol et al., Pretargeted radioimmunotherapy of cancer, RADIOIMMUNOTHERAPY OF CANCER, 2000, pp. 169-193
Receptor-mediated radionuclide therapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide: Preliminary report in cancer patients
Authors: Paganelli, G Zoboli, S Cremonesi, M Macke, HR Chinol, M
Citation: G. Paganelli et al., Receptor-mediated radionuclide therapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide: Preliminary report in cancer patients, CANC BIO R, 14(6), 1999, pp. 477-483
Sentinel node localization in primary melanoma: learning curve and results
Authors: Testori, A Bartolomei, M Grana, C Mezzetti, M Chinol, M Mazzarol, G Lazzari, I Paganelli, G Geraghty, JG Andreoni, B Veronesi, U
Citation: A. Testori et al., Sentinel node localization in primary melanoma: learning curve and results, MELANOMA RE, 9(6), 1999, pp. 587-593
Biokinetics and dosimetry in patients administered with In-111-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with Y-90-DOTATOC
Authors: Cremonesi, M Ferrari, M Zoboli, S Chinol, M Stabin, MG Orsi, F Maecke, HR Jermann, E Robertson, C Fiorenza, M Tosi, G Paganelli, G
Citation: M. Cremonesi et al., Biokinetics and dosimetry in patients administered with In-111-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with Y-90-DOTATOC, EUR J NUCL, 26(8), 1999, pp. 877-886
Clinical validation of the avidin/indium-111 biotin approach for imaging infection inflammation in orthopaedic patients
Authors: Lazzeri, E Manca, M Molea, N Marchetti, S Consoli, V Bodei, L Bianchi, R Chinol, M Paganelli, G Mariani, G
Citation: E. Lazzeri et al., Clinical validation of the avidin/indium-111 biotin approach for imaging infection inflammation in orthopaedic patients, EUR J NUCL, 26(6), 1999, pp. 606-614
Current status of commercial colloidal preparations for sentinel lymph node detection
Authors: Chinol, M Paganelli, G
Citation: M. Chinol et G. Paganelli, Current status of commercial colloidal preparations for sentinel lymph node detection, EUR J NUCL, 26(5), 1999, pp. 560-560
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
Authors: Paganelli, G Grana, C Chinol, M Cremonesi, M De Cicco, C De Braud, F Robertson, C Zurrida, S Casadio, C Zoboli, S Siccardi, AG Veronesi, U
Citation: G. Paganelli et al., Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin, EUR J NUCL, 26(4), 1999, pp. 348-357
Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients
Authors: Cremonesi, M Ferrari, M Chinol, M Stabin, MG Grana, C Prisco, G Robertson, C Tosi, G Paganelli, G
Citation: M. Cremonesi et al., Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients, EUR J NUCL, 26(2), 1999, pp. 110-120
Radiation protection in radioguided surgery of breast cancer
Authors: Cremonesi, M Ferrari, M Sacco, E Rossi, A De Cicco, C Leonardi, L Chinol, M Luini, A Galimberti, V Tosi, G Veronesi, U Paganelli, G
Citation: M. Cremonesi et al., Radiation protection in radioguided surgery of breast cancer, NUCL MED C, 20(10), 1999, pp. 919-924
Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping
Authors: Bartolomei, M Testori, A Chinol, M Gennari, R De Cicco, C Leonardi, L Zoboli, S Paganelli, G
Citation: M. Bartolomei et al., Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping, EUR J NUCL, 25(11), 1998, pp. 1489-1494
Risultati: 1-16 |